Comparing combined GLP-1 and SGLT2 treatments to SGLT2 alone in patients with fatty liver disease

Combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors is associated with a lower risk of all-cause hospitalization, mortality, and adverse events for metabolic dysfunction-associated steatotic liver disease.

• The primary composite outcomes showed a hazard ratio of 0.87 for combination therapy compared to SGLT2i alone.
• Combination therapy resulted in a 14% reduced risk of all-cause hospitalization (HR, 0.86).
• All-cause mortality risk was significantly lower with combination therapy, yielding a hazard ratio of 0.45.
• The risk of major adverse kidney events was reduced with combination therapy (HR, 0.72).
• Major adverse liver outcomes also showed a reduced risk with combination therapy (HR, 0.61).
• No additional benefits were observed from combination therapy compared to GLP-1RA monotherapy, except for all-cause mortality.

Simplified